Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX +8.33% EV-to-EBITDA is -2.24 as of Jul. 23, 2026. The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 854700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Imagion Biosystems's enterprise value is A$7.74 Mil.
Imagion Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.46 Mil. Therefore, Imagion Biosystems's EV-to-EBITDA for today is -2.24.
The historical rank and industry rank for Imagion Biosystems's EV-to-EBITDA or its related term are showing as below:
ASX:IBX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.39 Med: -1.48 Max: 1.25
Current: -2.24
During the past 9 years, the highest EV-to-EBITDA of Imagion Biosystems was 1.25. The lowest was -27.39. And the median was -1.48.
ASX:IBX's EV-to-EBITDA is ranked worse than 100% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.66
vs ASX:IBX: -2.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imagion Biosystems's PE Ratio (TTM) for today is calculated as:
Imagion Biosystems's share price for today is A$0.013.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Imagion Biosystems's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IBX vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's EV-to-EBITDA falls into.
Imagion Biosystems's current Enterprise Value is A$7.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (ASX:IBX) has a EV-to-EBITDA of -2.24 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Imagion Biosystems. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' EV-to-EBITDA too high?
Imagion Biosystems' current EV-to-EBITDA is -2.24. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 117 companies for EV-to-EBITDA. This places Imagion Biosystems in the lower half of its industry. The industry median EV-to-EBITDA is 14.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.66, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Imagion Biosystems. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current EV-to-EBITDA is -2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 98.8% below its estimated fair value. The current EV-to-EBITDA is -2.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current EV-to-EBITDA is -2.24 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
